Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azelastine + fluticasone (Synmosa Biopharma)
- Development stage
- Unknown
- Lead developer
- Synmosa Biopharma
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Synmosa Biopharma's azelastine/fluticasone nasal spray is a generic version of Dymista, a fixed-dose combination therapy for perennial allergic rhinitis. It combines azelastine hydrochloride, a selective H1-receptor antagonist, with fluticasone propionate, a corticosteroid. This dual-action formulation addresses both the histaminergic and inflammatory pathways of allergic rhinitis to alleviate symptoms like congestion, sneezing, and itching. Synmosa has evaluated this product in Phase 2 trials to demonstrate therapeutic equivalence to the branded reference.
- Other names
- azelastine hydrochloride/fluticasone propionate nasal sprayazelastine/fluticasone 137/50 mcg nasal spray
02
Targets
GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on azelastine + fluticasone (Synmosa Biopharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azelastine + fluticasone (Synmosa Biopharma).